Tarsus Pharmaceuticals (TARS) Competitors

$62.48 -2.70 (-4.14%)

Closing price 05/15/2026 04:00 PM Eastern

Extended Trading

$61.08 -1.40 (-2.25%)

As of 05/15/2026 05:00 PM Eastern

TARS vs. RDY, ABVX, CYTK, KRYS, and PRAX

Should you buy Tarsus Pharmaceuticals stock or one of its competitors? MarketBeat compares Tarsus Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Tarsus Pharmaceuticals include Dr. Reddy's Laboratories (RDY), Abivax (ABVX), Cytokinetics (CYTK), Krystal Biotech (KRYS), and Praxis Precision Medicines (PRAX). These companies are all part of the "pharmaceutical products" industry.

How does Tarsus Pharmaceuticals compare to Dr. Reddy's Laboratories?

Tarsus Pharmaceuticals (NASDAQ:TARS) and Dr. Reddy's Laboratories (NYSE:RDY) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, dividends, earnings, profitability, risk and valuation.

Dr. Reddy's Laboratories has a net margin of 12.90% compared to Tarsus Pharmaceuticals' net margin of -9.02%. Dr. Reddy's Laboratories' return on equity of 12.16% beat Tarsus Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tarsus Pharmaceuticals	-9.02%	-14.19%	-8.89%
Dr. Reddy's Laboratories	12.90%	12.16%	8.12%

Tarsus Pharmaceuticals currently has a consensus price target of $90.67, suggesting a potential upside of 45.11%. Dr. Reddy's Laboratories has a consensus price target of $16.90, suggesting a potential upside of 24.22%. Given Tarsus Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts plainly believe Tarsus Pharmaceuticals is more favorable than Dr. Reddy's Laboratories.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tarsus Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.78
Dr. Reddy's Laboratories	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Tarsus Pharmaceuticals has a beta of 0.52, suggesting that its share price is 48% less volatile than the broader market. Comparatively, Dr. Reddy's Laboratories has a beta of 0.27, suggesting that its share price is 73% less volatile than the broader market.

In the previous week, Tarsus Pharmaceuticals had 1 more articles in the media than Dr. Reddy's Laboratories. MarketBeat recorded 10 mentions for Tarsus Pharmaceuticals and 9 mentions for Dr. Reddy's Laboratories. Tarsus Pharmaceuticals' average media sentiment score of 0.71 beat Dr. Reddy's Laboratories' score of -0.25 indicating that Tarsus Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tarsus Pharmaceuticals	2 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Dr. Reddy's Laboratories	1 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

90.0% of Tarsus Pharmaceuticals shares are held by institutional investors. Comparatively, 3.9% of Dr. Reddy's Laboratories shares are held by institutional investors. 9.6% of Tarsus Pharmaceuticals shares are held by insiders. Comparatively, 2.0% of Dr. Reddy's Laboratories shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Dr. Reddy's Laboratories has higher revenue and earnings than Tarsus Pharmaceuticals. Tarsus Pharmaceuticals is trading at a lower price-to-earnings ratio than Dr. Reddy's Laboratories, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tarsus Pharmaceuticals	$535.08M	5.02	-$66.42M	-$1.14	N/A
Dr. Reddy's Laboratories	$3.58B	3.17	$484.20M	$0.58	23.46

Summary

Tarsus Pharmaceuticals beats Dr. Reddy's Laboratories on 10 of the 17 factors compared between the two stocks.

How does Tarsus Pharmaceuticals compare to Abivax?

Tarsus Pharmaceuticals (NASDAQ:TARS) and Abivax (NASDAQ:ABVX) are both mid-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, dividends, earnings, profitability, risk and valuation.

Tarsus Pharmaceuticals currently has a consensus price target of $90.67, suggesting a potential upside of 45.11%. Abivax has a consensus price target of $137.15, suggesting a potential upside of 19.75%. Given Tarsus Pharmaceuticals' higher probable upside, equities research analysts plainly believe Tarsus Pharmaceuticals is more favorable than Abivax.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tarsus Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.78
Abivax	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93

In the previous week, Tarsus Pharmaceuticals had 5 more articles in the media than Abivax. MarketBeat recorded 10 mentions for Tarsus Pharmaceuticals and 5 mentions for Abivax. Abivax's average media sentiment score of 0.84 beat Tarsus Pharmaceuticals' score of 0.71 indicating that Abivax is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tarsus Pharmaceuticals	2 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Abivax	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Tarsus Pharmaceuticals has a beta of 0.52, suggesting that its share price is 48% less volatile than the broader market. Comparatively, Abivax has a beta of 0.84, suggesting that its share price is 16% less volatile than the broader market.

Tarsus Pharmaceuticals has higher revenue and earnings than Abivax. Tarsus Pharmaceuticals is trading at a lower price-to-earnings ratio than Abivax, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tarsus Pharmaceuticals	$535.08M	5.02	-$66.42M	-$1.14	N/A
Abivax	N/A	N/A	-$380.27M	-$5.37	N/A

Abivax has a net margin of 0.00% compared to Tarsus Pharmaceuticals' net margin of -9.02%. Tarsus Pharmaceuticals' return on equity of -14.19% beat Abivax's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tarsus Pharmaceuticals	-9.02%	-14.19%	-8.89%
Abivax	N/A	-146.43%	-88.69%

90.0% of Tarsus Pharmaceuticals shares are held by institutional investors. Comparatively, 47.9% of Abivax shares are held by institutional investors. 9.6% of Tarsus Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Tarsus Pharmaceuticals beats Abivax on 10 of the 16 factors compared between the two stocks.

How does Tarsus Pharmaceuticals compare to Cytokinetics?

Cytokinetics (NASDAQ:CYTK) and Tarsus Pharmaceuticals (NASDAQ:TARS) are both mid-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, profitability, dividends, media sentiment, analyst recommendations, valuation, risk and institutional ownership.

Cytokinetics presently has a consensus price target of $98.55, indicating a potential upside of 29.93%. Tarsus Pharmaceuticals has a consensus price target of $90.67, indicating a potential upside of 45.11%. Given Tarsus Pharmaceuticals' higher probable upside, analysts plainly believe Tarsus Pharmaceuticals is more favorable than Cytokinetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cytokinetics	1 Sell rating(s)	3 Hold rating(s)	17 Buy rating(s)	1 Strong Buy rating(s)	2.82
Tarsus Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.78

In the previous week, Cytokinetics had 10 more articles in the media than Tarsus Pharmaceuticals. MarketBeat recorded 20 mentions for Cytokinetics and 10 mentions for Tarsus Pharmaceuticals. Tarsus Pharmaceuticals' average media sentiment score of 0.71 beat Cytokinetics' score of 0.38 indicating that Tarsus Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cytokinetics	4 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Tarsus Pharmaceuticals	2 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Cytokinetics has a beta of 0.38, indicating that its share price is 62% less volatile than the broader market. Comparatively, Tarsus Pharmaceuticals has a beta of 0.52, indicating that its share price is 48% less volatile than the broader market.

Tarsus Pharmaceuticals has higher revenue and earnings than Cytokinetics. Tarsus Pharmaceuticals is trading at a lower price-to-earnings ratio than Cytokinetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cytokinetics	$88.04M	107.20	-$784.96M	-$6.84	N/A
Tarsus Pharmaceuticals	$535.08M	5.02	-$66.42M	-$1.14	N/A

Tarsus Pharmaceuticals has a net margin of -9.02% compared to Cytokinetics' net margin of -784.02%. Cytokinetics' return on equity of 0.00% beat Tarsus Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cytokinetics	-784.02%	N/A	-52.86%
Tarsus Pharmaceuticals	-9.02%	-14.19%	-8.89%

90.0% of Tarsus Pharmaceuticals shares are owned by institutional investors. 2.6% of Cytokinetics shares are owned by company insiders. Comparatively, 9.6% of Tarsus Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Tarsus Pharmaceuticals beats Cytokinetics on 11 of the 17 factors compared between the two stocks.

How does Tarsus Pharmaceuticals compare to Krystal Biotech?

Krystal Biotech (NASDAQ:KRYS) and Tarsus Pharmaceuticals (NASDAQ:TARS) are both mid-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, profitability, dividends, media sentiment, analyst recommendations, valuation, risk and institutional ownership.

Krystal Biotech has a net margin of 53.92% compared to Tarsus Pharmaceuticals' net margin of -9.02%. Krystal Biotech's return on equity of 19.25% beat Tarsus Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Krystal Biotech	53.92%	19.25%	17.62%
Tarsus Pharmaceuticals	-9.02%	-14.19%	-8.89%

86.3% of Krystal Biotech shares are owned by institutional investors. Comparatively, 90.0% of Tarsus Pharmaceuticals shares are owned by institutional investors. 13.1% of Krystal Biotech shares are owned by company insiders. Comparatively, 9.6% of Tarsus Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Krystal Biotech has a beta of 0.5, indicating that its share price is 50% less volatile than the broader market. Comparatively, Tarsus Pharmaceuticals has a beta of 0.52, indicating that its share price is 48% less volatile than the broader market.

In the previous week, Tarsus Pharmaceuticals had 1 more articles in the media than Krystal Biotech. MarketBeat recorded 10 mentions for Tarsus Pharmaceuticals and 9 mentions for Krystal Biotech. Krystal Biotech's average media sentiment score of 1.04 beat Tarsus Pharmaceuticals' score of 0.71 indicating that Krystal Biotech is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Krystal Biotech	4 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Tarsus Pharmaceuticals	2 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Krystal Biotech presently has a consensus price target of $324.11, indicating a potential upside of 5.82%. Tarsus Pharmaceuticals has a consensus price target of $90.67, indicating a potential upside of 45.11%. Given Tarsus Pharmaceuticals' higher probable upside, analysts plainly believe Tarsus Pharmaceuticals is more favorable than Krystal Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Krystal Biotech	0 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.83
Tarsus Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.78

Krystal Biotech has higher earnings, but lower revenue than Tarsus Pharmaceuticals. Tarsus Pharmaceuticals is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Krystal Biotech	$389.13M	23.20	$204.83M	$7.48	40.95
Tarsus Pharmaceuticals	$535.08M	5.02	-$66.42M	-$1.14	N/A

Summary

Krystal Biotech beats Tarsus Pharmaceuticals on 11 of the 17 factors compared between the two stocks.

How does Tarsus Pharmaceuticals compare to Praxis Precision Medicines?

Praxis Precision Medicines (NASDAQ:PRAX) and Tarsus Pharmaceuticals (NASDAQ:TARS) are both mid-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, earnings, valuation, media sentiment, analyst recommendations, dividends, risk and institutional ownership.

Praxis Precision Medicines has a net margin of 0.00% compared to Tarsus Pharmaceuticals' net margin of -9.02%. Tarsus Pharmaceuticals' return on equity of -14.19% beat Praxis Precision Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Praxis Precision Medicines	N/A	-43.02%	-40.22%
Tarsus Pharmaceuticals	-9.02%	-14.19%	-8.89%

67.8% of Praxis Precision Medicines shares are held by institutional investors. Comparatively, 90.0% of Tarsus Pharmaceuticals shares are held by institutional investors. 2.7% of Praxis Precision Medicines shares are held by company insiders. Comparatively, 9.6% of Tarsus Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Praxis Precision Medicines has a beta of 2.76, indicating that its share price is 176% more volatile than the broader market. Comparatively, Tarsus Pharmaceuticals has a beta of 0.52, indicating that its share price is 48% less volatile than the broader market.

In the previous week, Praxis Precision Medicines had 13 more articles in the media than Tarsus Pharmaceuticals. MarketBeat recorded 23 mentions for Praxis Precision Medicines and 10 mentions for Tarsus Pharmaceuticals. Tarsus Pharmaceuticals' average media sentiment score of 0.71 beat Praxis Precision Medicines' score of 0.21 indicating that Tarsus Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Praxis Precision Medicines	4 Very Positive mention(s)	4 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Tarsus Pharmaceuticals	2 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Praxis Precision Medicines presently has a consensus price target of $592.67, indicating a potential upside of 73.00%. Tarsus Pharmaceuticals has a consensus price target of $90.67, indicating a potential upside of 45.11%. Given Praxis Precision Medicines' stronger consensus rating and higher possible upside, equities research analysts clearly believe Praxis Precision Medicines is more favorable than Tarsus Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Praxis Precision Medicines	2 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	4 Strong Buy rating(s)	2.95
Tarsus Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.78

Tarsus Pharmaceuticals has higher revenue and earnings than Praxis Precision Medicines. Tarsus Pharmaceuticals is trading at a lower price-to-earnings ratio than Praxis Precision Medicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Praxis Precision Medicines	$8.55M	1,117.09	-$303.27M	-$13.37	N/A
Tarsus Pharmaceuticals	$535.08M	5.02	-$66.42M	-$1.14	N/A

Summary

Praxis Precision Medicines beats Tarsus Pharmaceuticals on 9 of the 17 factors compared between the two stocks.

Get Tarsus Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TARS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TARS vs. The Competition

Export

Metric	Tarsus Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$2.69B	$3.31B	$6.38B	$12.30B
Dividend Yield	N/A	2.34%	2.81%	5.30%
P/E Ratio	-54.81	18.34	20.62	25.25
Price / Sales	5.02	287.72	554.13	75.49
Price / Cash	N/A	55.27	27.48	37.27
Price / Book	7.72	6.76	9.80	6.71
Net Income	-$66.42M	$24.40M	$3.57B	$336.00M
7 Day Performance	2.07%	4.14%	0.23%	0.12%
1 Month Performance	-7.08%	-4.80%	-2.54%	-0.18%
1 Year Performance	42.97%	62.87%	33.54%	30.62%

Tarsus Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TARS Tarsus Pharmaceuticals	3.3601 of 5 stars	$62.48 -4.1%	$90.67 +45.1%	+43.0%	$2.69B	$535.08M	N/A	50
RDY Dr. Reddy's Laboratories	3.2866 of 5 stars	$12.25 -6.8%	$16.90 +38.0%	-5.7%	$10.24B	$3.81B	15.94	27,811	News Coverage Earnings Report Analyst Downgrade
ABVX Abivax	3.2326 of 5 stars	$121.51 -0.5%	$137.15 +12.9%	+1,805.7%	$9.61B	N/A	N/A	61
CYTK Cytokinetics	2.824 of 5 stars	$74.86 +0.4%	$98.55 +31.6%	+144.7%	$9.30B	$88.04M	N/A	250	Analyst Forecast Insider Trade Options Volume Analyst Revision
KRYS Krystal Biotech	2.7264 of 5 stars	$311.12 -0.6%	$324.11 +4.2%	+134.5%	$9.18B	$389.13M	41.64	210	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TARS) was last updated on 5/17/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Tarsus Pharmaceuticals (TARS) Competitors

TARS vs. RDY, ABVX, CYTK, KRYS, and PRAX

How does Tarsus Pharmaceuticals compare to Dr. Reddy's Laboratories?

Summary

How does Tarsus Pharmaceuticals compare to Abivax?

Summary

How does Tarsus Pharmaceuticals compare to Cytokinetics?

Summary

How does Tarsus Pharmaceuticals compare to Krystal Biotech?

Summary

How does Tarsus Pharmaceuticals compare to Praxis Precision Medicines?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TARS vs. The Competition

Tarsus Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Tarsus Pharmaceuticals (TARS) Competitors

TARS vs. RDY, ABVX, CYTK, KRYS, and PRAX

How does Tarsus Pharmaceuticals compare to Dr. Reddy's Laboratories?

Is TARS or RDY more profitable?

Do analysts recommend TARS or RDY?

Which has more volatility & risk, TARS or RDY?

Does the media prefer TARS or RDY?

Do insiders & institutionals believe in TARS or RDY?

Which has better earnings & valuation, TARS or RDY?

Summary

How does Tarsus Pharmaceuticals compare to Abivax?

Do analysts recommend TARS or ABVX?

Does the media prefer TARS or ABVX?

Which has more volatility & risk, TARS or ABVX?

Which has better earnings & valuation, TARS or ABVX?

Is TARS or ABVX more profitable?

Do insiders & institutionals believe in TARS or ABVX?

Summary

How does Tarsus Pharmaceuticals compare to Cytokinetics?

Do analysts rate CYTK or TARS?

Does the media favor CYTK or TARS?

Which has more risk and volatility, CYTK or TARS?

Which has stronger valuation & earnings, CYTK or TARS?

Is CYTK or TARS more profitable?

Do institutionals & insiders believe in CYTK or TARS?

Summary

How does Tarsus Pharmaceuticals compare to Krystal Biotech?

Is KRYS or TARS more profitable?

Do institutionals & insiders believe in KRYS or TARS?

Which has more risk and volatility, KRYS or TARS?

Does the media favor KRYS or TARS?

Do analysts rate KRYS or TARS?

Which has stronger valuation & earnings, KRYS or TARS?

Summary

How does Tarsus Pharmaceuticals compare to Praxis Precision Medicines?

Is PRAX or TARS more profitable?

Do insiders and institutionals have more ownership in PRAX or TARS?

Which has more risk & volatility, PRAX or TARS?

Does the media favor PRAX or TARS?

Do analysts rate PRAX or TARS?

Which has higher valuation and earnings, PRAX or TARS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TARS vs. The Competition

Tarsus Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools